Risdiplam (Evrysdi)
Keyword(s):
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risdiplam (Evrysdi), powder for oral solution. Indication: Pre-NOC: for the treatment of spinal muscular atrophy; Final: for the treatment of spinal muscular atrophy in patients 2 months and older.